Fabien Moncaubeig

Trevi Therapeutics (United States) — United States

Engineering · Physical Sciences

4h-index140citations21works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

3D Printing in Biomedical Research(10), Pluripotent Stem Cells Research(6), CAR-T cell therapy research(4), Neuroscience and Neural Engineering(4), Pancreatic function and diabetes(3)

Publications21 total

Bioreactor-produced iPSCs-derived dopaminergic neuron-containing neural microtissues innervate and normalize rotational bias in a dose-dependent manner in a Parkinson rat model
Neurotherapeutics·2024· 3 citedOpen Access
CELL ENCAPSULATION AS A TOOL FOR STEM CELL BASED CELL THERAPY INDUSTRIALIZATION
Cytotherapy·2024
OFF-THE-SHELF BIOREACTOR PRODUCED, IPSC-DERIVED NEURAL MICROTISSUES CONTAINING DOPAMINERGIC NEURONS INNERVATE THE STRIATUM AND NORMALIZE BEHAVIOR IN A PARKINSON RAT MODEL
Cytotherapy·2024
Off-the-shelf bioreactor produced, iPSC-derived neural microtissues containing dopaminergic neurons innervate the striatum and normalize behaviour in a Parkinson rat model
Parkinsonism & Related Disorders·2024
Off-the-shelf Bioreactor Produced, iPSC-derived Neural Microtissues Containing Dopaminergic Neurons Innervate the Striatum and Normalize Behavior in a Parkinson Rat Model (P4-3.007)
Neurology·2024
iPSC: MICROTISSUE CELL THERAPY FOR PARKINSON’S DISEASE: SCALE-UP IN BIOREACTORS AND LATEST IN VIVO RESULTS
Cytotherapy·2023
Engineering 3D micro-compartments for highly efficient and scale-independent expansion of human pluripotent stem cells in bioreactors
Biomaterials·2023· 52 citedOpen Access
C-STEM: ENGINEERING NICHE-LIKE MICRO-COMPARTMENTS FOR OPTIMAL AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS
2021· 1 citedOpen Access
Up to 151.106 cumulated fold expansion of encapsulated hips cells in bioreactor over 28 days, and comparison with 2D culture and standard spheroid culture
Cytotherapy·2021
Estimating capital investment and facility footprint in cell therapy facilities
Biochemical Engineering Journal·2019· 12 citedOpen Access
Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement
Biochemical Engineering Journal·2018· 67 citedOpen Access
Development and optimization of large scale production of adenoviral vector and autologous insulin producing cell using iCELLis® 500 and Xpansion® 200 single-use bioreactors
Cytotherapy·2017
Cost-Effective Manufacturing Strategies For Feasible Commercialisation Of Autologous Car T-Cell Products
2017
Clinical Scale Manufacturing Of Autologous Insulin Producing Liver Cells For The Treatment Of Diabetes
2017
A method for estimating capital investment and facility footprint of cell therapy facilities
2017
Facility design concepts for adoptive T-cell immunotherapy
2017
Process economics of CAR T-cell therapy products
2016
Determining the commercial feasibility of autologous CAR T-cell products
2016
Hydrodynamics in a disposable rectangular parallelepiped stirred bioreactor with elliptic pendulum motion paddle
Biochemical Engineering Journal·2014· 5 citedOpen Access
Enabling cell based therapy manufacturing scaling up cell culture from multitray stack to closed and controlled multiplate bioreactor
Cytotherapy·2013
page 1 of 2Next →

Frequent Co-authors

E. Luquet(9), Maxime Feyeux(9), Justine Plétenka(8), Basile Gurchenkov(8), Kévin Alessandri(8), Suzanne S. Farid(7), N. Prudon(5), Lucía Cordero-Espinoza(5), L. Milvoy(5), Léa Poinçot(5), Thibault Dufourd(5), Emilie Faggiani(5), Tania Pereira Chilima(5), Maëlle Demarco(4), Chloé Morel(4), Pauline Morand(4), Hélène Wurtz(4), Guillaume Dabée(4), Erwan Bézard(4), Miguel Fidalgo(4)